EMA designates uniQure’s gene therapy for hemophilia a priority
Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent…
Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent…
We've compiled a list of some of the latest advances of biotech in the field…
UniQure has received Breakthrough Therapy Designation from the FDA, granting fast track to its gene therapy…
Last year was a bad year for biotech as an industry, but it was particularly…
UniQure's gene therapy for Hemophilia B is performing well in clinical trials, but the company faces…
Promethera is collecting cash to fuel its liver disease program that revolves around HepaStem. I…
UniQure just announced a new R&D plan designed to save up to €27M over the…
Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy…
The Swiss pharma is gearing up for a battle with Novo Nordisk in Hemophilia, but…
uniQure has new data from the Phase I/II trial of its gene therapy for Hemophilia…
Sobi has received market approval by the European Comission for Alprolix, a long-duration protein therapy…
The Hemophilia Aid Program has just touched down the first batch of treatments in its…